DJIA 17,067.56 -30.89 -0.18%
NASDAQ 4,598.19 17.92 0.39%
S&P 500 2,002.28 -1.09 -0.05%
market minute promo

Amgen, Inc. (NASDAQ: AMGN)

137.96 -1.42 (-1.02%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

AMGN $137.96 -1.02%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $139.62
Previous Close $139.38
Daily Range $137.20 - $139.93
52-Week Range $105.76 - $139.93
Market Cap $104.8B
P/E Ratio 21.34
Dividend (Yield) $2.44 (1.8%)
Ex-Dividend Date
Dividend Pay Date
08/12/14
09/05/14
Volume 3,287,757
Average Daily Volume 3,417,847
Current FY EPS $8.24

Sector

Healthcare

Industry

Drugs

Amgen, Inc. (AMGN) Description

A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. Website: http://www.amgen.com/

News & Commentary

3 Reasons Eli Lilly & Co.'s Stock Could Rise

With earnings tumbling over the patent cliff, can diabetes and oncology transform Eli Lilly into a Big Pharma turnaround story?

United Therapeutics Soars on Remodulin Patent Case Win - Analyst Blog

United Therapeutics Soars on Remodulin Patent Case Win - Analyst Blog

Regeneron/Sanofi Presents Encouraging Alirocumab Data - Analyst Blog

AMGN, MRK And PFE, 3 Drugs Stocks Pushing The Industry Lower

Amgen - Quickly Generating Growth

New Lifetime High For Amgen (AMGN)

PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for September 03, 2014

Great Cholesterol Drug Data From Regeneron Pharmaceuticals Inc. and Sanofi SA, but Read the Fine Pri

Regeneron Pharmaceuticals and Sanofi's PCSK9 drug, alirocumab, reduces cardiovascular events, but the data come from a post-hoc analysis.

Pfizer's C. Difficile Vaccine Gets Fast Track Status - Analyst Blog

Amgen Submits Regulatory Application for PCSK9 Inhibitor - Analyst Blog

See More AMGN News...

AMGN's Top Competitors

AMGN $137.96 (-1.02%)
Current stock: AMGN
GILD $109.36 (1.67%)
Current stock: GILD
CELG $95.09 (0.07%)
Current stock: CELG
$0.00 (0.00%)
Current stock: